Can people with type 1 diabetes take tirzepatide?

You have type 1 diabetes and your GP mentioned tirzepatide, here's where things actually stand

Picture this: you've been managing type 1 diabetes for years, your weight has crept up despite your best efforts, and someone in a clinic or online suggests tirzepatide might help. It's a reasonable thing to wonder about. Tirzepatide acts on two gut-hormone pathways (GIP and GLP-1 receptors) to reduce appetite and slow gastric emptying, and it produces significant weight reduction in people with obesity. Those effects don't switch off because a person has type 1 rather than type 2 diabetes. The mechanism is real. The problem is the licensed evidence base and the safety context around it.

In the UK, Mounjaro's licence covers adults with obesity (BMI 30 or above, or 27 or above with a weight-related condition) and adults with type 2 diabetes. Type 1 diabetes is a different condition with a fundamentally different relationship to insulin: the pancreas produces none of its own. GLP-1 medicines were developed and trialled in populations where some endogenous insulin production remains, and the MHRA's authorisation reflects that evidence. The NHS tirzepatide information page lists type 1 diabetes among conditions requiring careful prescriber discussion, because the interaction between tirzepatide and insulin regimens is not well characterised in large clinical trials.

Small investigational studies have looked at GLP-1 and dual agonists in type 1 populations (and results are not without interest) but none of this research has translated into UK prescribing guidance. That gap matters.

The hypoglycaemia risk is the central clinical concern

For someone taking insulin to manage type 1 diabetes, adding tirzepatide introduces a meaningful risk of low blood sugar. Tirzepatide reduces food intake significantly, slows how quickly food moves through the stomach, and alters post-meal glucose dynamics. If insulin doses are not adjusted to reflect those changes (which is genuinely difficult to do without specialist input) the risk of hypoglycaemia rises. This isn't a theoretical footnote; it is the primary reason diabetes teams approach this combination with caution.

The January 2026 MHRA Drug Safety Update on GLP-1 medicines highlighted pancreatitis as a known risk worth monitoring, but for type 1 patients the insulin interaction question comes first. Any weight management plan that involves changing appetite, carbohydrate absorption and gastric transit needs to be mapped against an existing insulin regimen with precision. Keeping your pen in the fridge door and your glucose meter nearby captures the daily reality: these two medicines share your routine, and they interact within it.

The detailed clinical picture of tirzepatide and type 1 diabetes explores what the available research actually found, and it's worth reading alongside any conversation you have with your specialist. If you want to understand whether type 1 diabetics can take Mounjaro and what the evidence actually shows, that page sets out the position clearly. General information about tirzepatide and diabetes more broadly covers how the licence applies across different diabetes presentations.

Who to talk to, and what a legitimate private clinic can help with

If you have type 1 diabetes and you're looking for support with weight management, the right starting point is your diabetes specialist team, an endocrinologist or a diabetologist who knows your insulin regimen, your HbA1c history, and your individual risks. Weight management medicines are increasingly part of specialist conversations, but those conversations need to happen in the right setting, not via a general online questionnaire.

At nume, our prescribers carry out a same-day clinical review of every consultation, a real clinician reads your answers, not an automated system. For most people with type 2 diabetes and obesity, Mounjaro is a treatment we can consider and prescribe privately, without waiting lists or referrals. For people with type 1 diabetes, it is a different situation: the clinical complexity means this needs specialist diabetes input that goes beyond what a weight management consultation can provide. We will always tell you that plainly.

If you're exploring your options more broadly, our weight loss treatment overview explains what is currently licensed and clinically suitable for different situations, and the team via our contact page can answer questions before you start a consultation. For context on how tirzepatide is used in type 2 diabetes specifically, this page covers the licensed evidence in that population. Our clinical lead oversees prescribing standards across the service, so if you want to understand our approach, that's the right place to look.

The short answer for a type 1 diabetic asking about whether they can take Mounjaro: not licensed, not straightforward, and genuinely something to pursue through your specialist team rather than around them.